Yusuf M, et al. - Clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat patients 70 years of age or older with newly diagnosed glioblastoma (GBM) were investigated in this phase II study. The patients received HRT to a dose of 34 Gy given in ten fractions over 2 weeks, delivered with concurrent and adjuvant TMZ. Outcomes suggest that these elderly patients with GBM had good tolerance with HRT delivered over 2 weeks with concurrent and adjuvant TMZ without compromising clinical outcomes.